Issue Highlights Clinical Gastroenterology and Hepatology Stephen B. Hanauer  Clinical Gastroenterology and Hepatology  Volume 13, Issue 3, Pages 413-415 (March 2015) DOI: 10.1016/j.cgh.2015.01.004 Copyright © 2015 AGA Institute Terms and Conditions

Figure 3 Predictive role of risk panel. Relapse and colectomy rate based on a risk panel including 5 independent risk factors, namely absence of short-term complete clinical response, absence of short-term mucosal healing, pANCA positivity, baseline albumin level less than 35 g/L, and baseline CRP level greater than 5 mg/L: (A) time to relapse, (B) time to colectomy, (C) clinical relapse rate within 12 months, and (D) colectomy rate within 60 months. Clinical Gastroenterology and Hepatology 2015 13, 413-415DOI: (10.1016/j.cgh.2015.01.004) Copyright © 2015 AGA Institute Terms and Conditions

Figure 4 Proposed algorithm for discontinuation of immunomodulator (IMM) in patients with durable response under combination treatment. ADA, adalimumab; IFX, infliximab; TL, trough level; TNF, tumor necrosis factor. Clinical Gastroenterology and Hepatology 2015 13, 413-415DOI: (10.1016/j.cgh.2015.01.004) Copyright © 2015 AGA Institute Terms and Conditions